

Metabotropic Glutamate 1 α and Adenosine A1 Receptors Assemble into Functionally Interacting Complexes*

Received for publication, August 2, 2000, and in revised form, February 12, 2001
Published, JBC Papers in Press, February 13, 2001, DOI 10.1074/jbc.M006960200

Francisco Ciruela \ddagger §¶, Marisol Escriche \ddagger , Javier Burgueño \ddagger , Ester Angulo \ddagger , Vicent Casadó \ddagger , Mikhail M. Soloviev \S , Enric I. Canela \ddagger , Josefa Mallol \ddagger , Wai-Yee Chan \S , Carmen Lluís \ddagger , R. A. Jeffrey McIlhinney \S , and Rafael Franco \ddagger

From the \ddagger Department of Biochemistry and Molecular Biology, University of Barcelona, 08028 Barcelona, Spain and \S Medical Research Council Anatomical Neuropharmacology Unit, Oxford OX13TH, United Kingdom

Recently, evidence has emerged that seven transmembrane G protein-coupled receptors may be present as homo- and heteromers in the plasma membrane. Here we describe a new molecular and functional interaction between two functionally unrelated types of G protein-coupled receptors, namely the metabotropic glutamate type 1 α (mGlu $_{1\alpha}$ receptor) and the adenosine A1 receptors in cerebellum, primary cortical neurons, and heterologous transfected cells. Co-immunoprecipitation experiments showed a close and subtype-specific interaction between mGlu $_{1\alpha}$ and A1 receptors in both rat cerebellar synaptosomes and co-transfected HEK-293 cells. By using transiently transfected HEK-293 cells a synergy between mGlu $_{1\alpha}$ and A1 receptors in receptor-evoked [Ca $^{2+}$] $_i$ signaling has been shown. In primary cultures of cortical neurons we observed a high degree of co-localization of the two receptors, and excitotoxicity experiments in these cultures also indicate that mGlu $_{1\alpha}$ and A1 receptors are functionally related. Our results provide a molecular basis for adenosine/glutamate receptors cross-talk and open new perspectives for the development of novel agents to treat neuropsychiatric disorders in which abnormal glutamatergic neurotransmission is involved.

Glutamate is the major excitatory neurotransmitter in the central nervous system (1), and its function through ionotropic and metabotropic (mGlu) 1 glutamate receptors can be modulated by other neurotransmitters/neuromodulators (2). Eight members of the mGlu receptor family have been identified and categorized into three subgroups on the basis of their sequence homology, agonist selectivity, and signal transduction pathway. Group I contains mGlu $_1$ and mGlu $_5$ subtypes, which are coupled to phospholipase C in transfected cells, and have quisqualic acid as their most potent agonist. Five splice variants of mGlu1 receptor have been described, mGlu $_{1\alpha}$, mGlu $_{1\beta}$, mGlu $_{1c}$,

mGlu $_{1d}$, and mGlu $_{1e}$ receptors (3, 4), all of them differing in the length of their C-terminal tail. The functional significance of the different splice variants has not yet been fully explored. It has been suggested that the C-terminal tail, which is intracellular, might play a role in the subcellular targeting of the receptor (5). Recently, we have reported that the C terminus of mGlu $_{1\alpha}$ receptor interacts with tubulin (6) and that it can regulate the cell surface expression of the receptor (7) and its plasma membrane anchoring (8, 9).

Adenosine is an important neuromodulator implicated in a variety of brain activities, particularly those related to sleep and ischemic-hypoxic episodes (10). This ubiquitous nucleoside exerts its actions via specific receptors, four of which (A1, A2A, A2B, and A3) have been cloned (11). The A1R is functionally coupled to members of the pertussis toxin-sensitive family of G proteins (G $_{i1}$, G $_{i2}$, G $_{i3}$, and G $_o$), and its activation regulates several membrane and intracellular proteins such as adenylate cyclase, Ca $^{2+}$ channels, K $^+$ channels, and phospholipase C (11). Of the multiple neurophysiological actions of adenosine, inhibition of glutamate neurotransmission has been observed in several brain regions (12) and is probably a result of the inhibition of presynaptic calcium influx (13). Apart from this inhibitory effect, there is some evidence documenting functional interactions between adenosine and glutamate receptors in the central nervous system. Of particular interest are reports of group I mGlu receptors signaling being enhanced by group II mGlu receptors in hippocampal and cerebrotical slices (14–16) and by adenosine A1 receptors in cultured hippocampal type 1 astrocytes (17). Very recently, Toms and Roberts (18) have described that type 2 astrocytes contain group I mGlu receptors coupled to [Ca $^{2+}$] $_i$ signaling and that co-activation of adenosine A1 receptors enhances group I mGlu-evoked [Ca $^{2+}$] $_i$ responses in these cells via G $_{i/o}$ G protein-mediated mechanism. Despite these observations, no clear molecular mechanism of this interaction between glutamate and adenosine receptors has been provided yet.

Here we report a molecular interaction between metabotropic glutamate receptor type 1 α and the adenosine A1 receptor, two members of different GPCR families. This interaction suggests that both receptors may form part of a signaling complex *in vivo* that could play a critical role in fine-tuning neurotransmission at glutamatergic synapses.

EXPERIMENTAL PROCEDURES

Cell Culture, Generation of mGlu, Truncated Mutant, and Transfection—Human embryonic kidney cells, HEK-293, were grown as described (9). Rat mGlu $_1$ receptor was truncated after amino acid position 885 (see Fig. 4). A stop codon was introduced into the coding sequence of the FLAG epitope containing mGlu $_{1\alpha}$ receptor cDNA by polymerase chain reaction (8). Forward primer was MGR1-F7 (5'-GGCCCTGGGG-TGCATGTTACTC-3', position 2833–2855 of the mGlu $_1$ receptor cDNA

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¶ Recipient of a fellowship from The Wellcome Trust and currently holding a research contract from the Catalan Commission for Research and Technological Innovation. To whom correspondence should be addressed: Dept. de Bioquímica i Biologia Molecular, C/Martí i Franquès, 1, 08028 Barcelona, Spain. Tel.: 34-934021213; Fax: 34-934021219; E-mail: recep@sun.bq.ub.es.

1 The abbreviations used are: mGlu, metabotropic glutamate; GPCR, G protein-coupled receptors; A1R, adenosine A1 receptors; NMDA, N-methyl-D-aspartate; R-PIA, (R)-phenylisopropyladenosine; Ab, antibody; GABA $_A$, γ -aminobutyric acid A; PAGE, polyacrylamide gel electrophoresis.

(GenBank™ accession number X57569)), and reverse primer was MGR1-R22 (5'-CGTCTCGAGTTTAATTCCTGCCCGGGCTTCTTT-3', position 3026 to 2992, but also encoded *XhoI* restriction site (underlined) and a stop codon (shown in bold)). The *BspEI-XhoI* fragment of the amplified cDNA sequence, which contained a stop codon, was used to substitute corresponding fragment of rat mGlu_{1α} receptor cDNA in pcDNA3 vector thus resulting in mGlu_{1α}-M7 construct (see Fig. 4). The truncation introduced was confirmed by DNA sequencing.

For the transient expression of mGlu_{1α}, mGlu_{1β}, mGlu₁-M7, and/or A1 receptors, cells were transiently transfected with 10 μg of cDNA encoding the rat metabotropic glutamate receptors and/or rat adenosine A1 receptor (ratio 1:1; pcDNA containing LacZ reporter was used to equilibrate the amount of total DNA) by calcium phosphate precipitation (19). The cells were used for experimentation at either 24 or 48 h after transfection. Cells were grown in glutamate-free medium (ICN, Basingstoke, UK) in the absence of both glutamine and glutamic acid for 3 h before their use.

Primary Cultures and N-Methyl-D-Aspartate (NMDA)-induced Neurotoxicity—Cortical hemispheres from E16 rat embryos were dissected, and primary cultures of rat cortical neurons were prepared as described previously (9) and used after 14–21 days *in vitro*. To determine the NMDA-mediated neurotoxicity, the culture-conditioned medium was collected, and the cortical neurons were washed once with serum-free B27-supplemented Neurobasal medium (Life Technologies, Inc.) containing 50 μg/ml gentamicin (Sigma) (BNG medium) and preincubated with or without 30 μM NMDA (Tocris, Bristol, UK) for 10 min at 37 °C, as described previously (20). Quisqualic acid (100 μM) (Tocris, Bristol, UK) and/or (*R*)-phenylisopropyladenosine (R-PIA) (100 nM) (Sigma) were transiently applied for 1 min during the 5 min prior to the addition of NMDA (20) and then added together with the NMDA. Neurons, after being washed with the BNG medium, were returned to the culture-conditioned medium and further incubated at 37 °C for 24 h. After the NMDA pulse (24 h), neurons were stained with propidium iodide (80 μg/ml) for 5 min and examined immediately with a standard epillumination fluorescence microscope. Neuronal injury was determined by the ability of propidium iodide (Sigma) to penetrate and interact with DNA in damaged neurons, yielding red fluorescence.

Immunostaining—For immunohistochemistry, rat cerebellum was embedded in OCT and frozen in liquid nitrogen-cooled isopentane. Eight micrometer sections were cut on a cryostat cooled to -18 °C. Sections were collected onto SuperFrost Plus (BDH, Darmstadt, Germany) slides, air-dried, and stored at -70 °C. Sections were blocked for 30 min in 10% donkey serum in Tris-buffered saline (TBS) (150 mM NaCl, 50 mM Tris-HCl, pH 7.5). Slides were incubated with affinity-purified anti-mGlu_{1α} receptor (F2-Ab, 2–4 μg/ml) (21) and affinity-purified anti-A1R (PC21, 5–10 μg/ml) (22) for 1 h at room temperature and then washed twice for 5 min in TBS. Fluorescein isothiocyanate-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) was applied in TBS at a dilution of 1:100. Section were rinsed and mounted with Vectashield immunofluorescence medium (Vector Laboratories, Orton Southgate, UK).

For immunocytochemistry, HEK-293 cells transiently transfected (see above) and primary cultures of rat cortical neurons were fixed in 4% paraformaldehyde for 15 min and washed with phosphate-buffered saline containing 20 mM glycine (buffer A) to quench the aldehyde groups. Where indicated, cells were permeabilized with buffer A containing 0.2% Triton X-100 for 5 min. Cells were labeled for 1 h at room temperature with the indicated primary antibody, washed, and stained with fluorescein-conjugated donkey anti-rabbit IgG antibody (1/100) and Texas Red-conjugated donkey anti-mouse IgG antibody (1/100). Coverslips were rinsed for 30 min in buffer B and mounted with Vectashield immunofluorescence. Confocal microscope observations were made with a Leica TCS NT (Leica Lasertechnik GmbH, Heidelberg, Germany) confocal scanning laser microscope adapted to an inverted Leitz DMIRBE microscope.

Immunoprecipitation—Rat cerebellum synaptosomes (6) or transfected HEK cells were solubilized in ice-cold lysis buffer (phosphate-buffered saline, pH 7.4, containing 1% (v/v) Nonidet P-40, 0.5% (w/v) sodium deoxycholic acid, and 0.1% (w/v) SDS) for 1 h on ice. The solubilized preparation was then centrifuged at 80,000 × *g* for 90 min. The supernatant (1 mg of protein/ml) was processed for immunoprecipitation as described before (6) using the anti-A1R antibody (PC21-Ab) or anti-FLAG monoclonal antibody (Sigma, Clone M2; 10 μg/ml). The immune complexes were dissociated in SDS-PAGE sample buffer by heating to 100 °C for 5 min and resolved by SDS-polyacrylamide gel electrophoresis in 7% gels (23). Proteins were transferred to polyvinylidene difluoride membranes (Immobilon-P, Millipore, Watford, UK) using a semi-dry transfer system and immunoblotted using the primary

antibodies indicated in the figure legends and horseradish-peroxidase-conjugated swine anti-rabbit IgG (Dako, Ely, UK) as a secondary antibody. The immunoreactive bands were developed with the enhanced chemiluminescence detection kit (Pierce), as described previously (6).

Ligand Binding Experiments—Membrane suspensions from transiently transfected HEK cells were obtained according to Casadó *et al.* (24). For competition experiments to determine the K_D values, 30 nM [³H]quisqualic acid (Amersham Pharmacia Biotech) or 20 nM [³H]R-PIA (Amersham Pharmacia Biotech) binding to membrane suspensions of HEK cells transiently expressing mGlu_{1α}-FLAG receptor or A1R (0.5 mg protein/ml) were carried out at 25 °C in 50 mM Tris-HCl buffer, pH 7.4, in the absence or presence of increasing amounts of quisqualic acid or R-PIA, as described previously (24). After 2 h of radioligand incubation, free and membrane-bound radioligand were separated by rapid filtration in a Brandel cell harvester through Whatman GF/C filters. Filters were transferred to scintillation vials containing 10 ml of Formula 989 (PerkinElmer Life Sciences). Radioactivity was counted using a Packard 1600 TRI-CARB scintillation counter with 50% of efficiency. Competition data were fitted using a non-linear regression program as described previously (24, 25).

To determine the density of expressed receptors in HEK cells transiently transfected with A1R, mGlu_{1α}-FLAG or A1R plus mGlu_{1α}-FLAG, the binding of 70 nM [³H]quisqualic and 15 nM [³H]R-PIA was performed as described above, and the B_{max} was deduced taking into account the K_D values as described previously (24).

Calcium Determination—Transiently transfected HEK cells (10⁶ cell/ml) were loaded with 5 μM Fura-2/AM for 30 min at 37 °C. Cells were washed and subsequently incubated in HBSS containing 0.2 units/ml adenosine deaminase. Calcium peak induction was achieved by the addition of R-PIA or quisqualic acid. Intracellular calcium was determined at 37 °C in a dual-wavelength Shimadzu RF-5000 spectrofluorometer (Shimadzu Europe, Duisberg, Germany) by using the excitation wavelength ratio of 334/366 nm with emission cut-off at 500 nm. Free calcium concentration was calculated as described previously (26).

RESULTS

Interaction of mGlu_{1α} and A1 Receptors in Rat Cerebellum—Immunohistochemical studies showed that mGlu_{1α} receptors are present in cerebellum, and its expression is mainly restricted to the cell body and the dendritic tree of Purkinje cells and basket cells located in the molecular layer (Fig. 1*a*). This is in agreement with the previously described location of these receptors in an annulus, which surrounds the post-synaptic density (27). The A1R had a more ubiquitous distribution in cerebellum being expressed in Purkinje cells and basket cells, as mGlu_{1α} receptor, and also in granule cells (Fig. 1*a*). This fits with the localization of adenosine A1 receptors both presynaptically and postsynaptically (28). In addition, metabotropic glutamate receptor type 1α and adenosine A1 receptors showed a similar distribution in human cerebral cortex being expressed in large pyramidal cells located at layers V and II/III (data not shown).

The *in vivo* co-distribution of mGlu_{1α} and A1 receptors in some cerebellar neurons (Fig. 1*a*) suggests a potential interaction between both receptors at precise brain areas. The existence of mGlu_{1α}/A1 receptors' heteromers was assayed by co-immunoprecipitation experiments using a soluble extract from rat cerebellum synaptosomes that had been shown by Western blotting to contain both adenosine A1 (Fig. 1*b*, lane 1) and mGlu_{1α} receptors (Fig. 1*b*, lane 2). When this soluble extract was immunoblotted using a specific antibody against A1 receptor (PC21-Ab), two bands of around 39 and 74 kDa of molecular size were shown (Fig. 1*b*, lane 3); these bands, which are glycosylated proteins (29), have been demonstrated previously to correspond to the adenosine A1 receptor monomer and dimer, respectively (22). On the other hand, a specific antibody against the mGlu_{1α} receptor (F2-Ab) immunoblotted in the cerebellum synaptosomes extract a band with apparent molecular size of 150 kDa that corresponds to the mGlu_{1α} receptor (Fig. 1*b*, lane 4), which is a glycosylated protein as it has been described previously (21, 30). From this extract, the antibody against A1R (PC11-Ab) immunoprecipitated a band of 150 kDa




FIG. 1. Interaction of mGlu_{1α} and A1 receptors in rat cerebellum. *a*, 8- μ m cryosections from rat cerebellum were stained with anti-mGlu_{1α} receptor antibody (F2-Ab; 4 μ g/ml) and anti-A1R antibody (PC21-Ab; 10 μ g/ml). F2-Ab immunoreactivity is confined mainly to the molecular layer (ML) and it stains Purkinje cells and basket cells. PC21-Ab stains Purkinje cells and basket cells in the molecular layer as well as granule cells in the granular layer (GL). *b*, co-immunoprecipitation of mGlu_{1α} and A1 receptors from extracts of rat cerebellum synaptosomes. Extracts and immunoprecipitates (IP) (see "Experimental Procedures") were analyzed by SDS-PAGE and immunoblotted (IB) using anti-mGlu_{1α} receptor antibodies (F2-Ab; 5 μ g/ml) or anti-A1R antibodies (PC11-Ab; 10 μ g/ml). Immunoreactive bands were detected with swine anti-rabbit (1:5000) secondary antibody conjugated to horseradish peroxidase followed by chemiluminescence detection. IgG indicates the position of the immunoglobulins used in the immunoprecipitation.

that was detected by the F2-Ab (Fig. 1*b*). This band was also immunoprecipitated using a different antibody against mGlu₁ receptor (F1-Ab) but was not present in immunoprecipitates generated with an irrelevant antibody (Fig. 1*b*, lane 5). It should be noted that the efficacy of immunoprecipitation of mGlu_{1α} receptor by the anti-adenosine receptor antibody was much less than when an anti-mGlu₁ receptor antibody was used. Overall, these results indicate that there are zones in which mGlu_{1α} and A1 receptors do not co-distribute and that there are zones in which the two receptors co-distribute and form aggregates (heteromers).

Interaction of mGlu_{1α} and A1 Receptors in Transiently Transfected HEK-293 Cells—The close association of mGlu_{1α} and A1 receptors was subsequently studied in co-transfected HEK-293 cells by co-immunoprecipitation and double immunolabeling experiments. By confocal microscopy analysis of HEK-293 cells transiently transfected with the cDNAs for mGlu_{1α}-FLAG and A1 receptors, a marked overlap in the distribution of the two proteins was found (Fig. 2). As deduced from horizontal optical sections of permeabilized (+Triton) and nonpermeabilized (−Triton) cells, co-localization was not restricted to the plasma membrane but extended to intracellular compartments. Interestingly, when the double immunolabeling experiment was performed on HEK-293 cells transiently transfected with the cDNAs for mGlu_{1β}-FLAG, the C-terminal splice variant of mGlu₁ receptor (Fig. 4*a*), and A1 receptors, no co-localization between both proteins was observed at the plasma membrane level (Fig. 2), suggesting a specificity for the co-localization between mGlu_{1α}-FLAG and A1 receptors.

From co-transfected HEK cell extracts, the antibody against A1R (PC11-Ab) co-immunoprecipitated a band of 150 kDa, which corresponds to the mGlu_{1α}-FLAG receptor (Fig. 3, lane




FIG. 2. Immunofluorescence localization of mGlu_{1α}, mGlu_{1β}, and A1 receptors in HEK-293 cells. Cells were transiently transfected with cDNAs encoding for mGlu_{1α}-FLAG or mGlu_{1β}-FLAG and A1R. After 48 h cells were washed, fixed (−Triton), and/or permeabilized (+Triton) and processed for immunostaining with anti-FLAG monoclonal antibody (Sigma, Clone M2; 10 μ g/ml) and anti-A1R affinity-purified antibody (PC21-Ab, 5 μ g/ml). The bound primary antibodies were detected using either fluorescein-conjugated donkey anti-mouse IgG antibody (1/50) or Texas Red-conjugated donkey anti-rabbit (1/50). Cells were analyzed by double immunofluorescence with a confocal microscopy. Superimposition of images reveals mGlu_{1α} (green) and A1 (red) receptors co-localization in yellow. The images show a single horizontal section of representative cells. Scale bar, 10 μ m.

5). This band did not appear in immunoprecipitates from cells transfected with the cDNA for either A1 receptors (Fig. 3, lane 4) or mGlu_{1α} (Fig. 3, lane 6) or when an irrelevant antibody was used (data not shown). Conversely, when we immunoprecipitate with the FLAG antibody to pull down mGlu_{1α}-FLAG receptor in the transiently co-transfected HEK-293 cells, and subsequently the immunoprecipitates were analyzed by SDS-PAGE and immunoblotted using anti-A1R antibodies, a band which corresponds to the A1R was observed (Fig. 3, lane 11). Interestingly, no immunoprecipitation of mGlu_{1β} receptor, the C-terminal splice variant of mGlu₁ receptor (Fig. 4*a*), was obtained from co-transfected cells using the antibody against A1R (PC11-Ab) (Fig. 4*b*, lane 7). Additionally, the construct mGlu₁-M7, a deleted mutant close to the splice variant site of the mGlu₁ receptor (Fig. 4*a*), also did not interact with A1R (Fig. 4*b*, lane 8). Overall, these results suggest that the C-terminal tail of the mGlu_{1α} receptor (Fig. 4*a*) is implicated in the interaction of both receptors.

To test the functional significance of an mGlu_{1α}/A1 receptors interaction, measurements of calcium mobilization in co-transfected HEK-293 cells were performed. In HEK cells transiently expressing A1R or A1R plus mGlu_{1α}-FLAG R-PIA mobilized intracellular calcium in a concentration-dependent manner, with an EC₅₀ value of 46.8 \pm 4.4 nM for the single expressing A1R cells or 45.7 \pm 5.1 nM for the doubly A1R plus mGlu_{1α}-FLAG expressing cells. On the other hand, in these cells quisqualic acid also mobilized intracellular calcium in a concentration-dependent manner, with an EC₅₀ value of 4.1 \pm 1.1 μ M for the single expressing mGlu_{1α}-FLAG cells or 5.6 \pm 1.1 μ M for the doubly A1R plus mGlu_{1α}-FLAG expressing cells. The densities of the transiently expressed receptors were controlled by




FIG. 3. Interaction of mGlu_{1α} and A1 receptors in transiently transfected HEK-293 cells. Cells transiently expressing A1R alone (lanes 1 and 7), A1R plus mGlu_{1α}-FLAG (lanes 2 and 8), or mGlu_{1α}-FLAG alone (lanes 3 and 9) were washed and solubilized in ice-cold lysis buffer and processed for immunoprecipitation using anti-A1R antibodies (PC11-Ab; 10 μg/ml; lanes 4–6) and anti-FLAG monoclonal antibody (Sigma, Clone M2; 10 μg/ml; lanes 10–12). Solubilized membranes (Crude, lanes 1–3 and 7–9) and immunoprecipitates (IP, lanes 4–6 and 10–12) were analyzed by SDS-PAGE and immunoblotted (IB) using anti-mGlu_{1α} receptor antibodies (F2-Ab; 5 μg/ml) or anti-A1R antibodies (PC21-Ab; 10 μg/ml). Immunoreactive bands were detected as before. IgG indicates the position of the immunoglobulins used in the immunoprecipitation.




FIG. 4. Specificity of the interaction between mGlu_{1α} and A1 receptors in transiently transfected HEK-293 cells. *a*, schematic representation of the primary structure of rat mGlu_{1α} and mGlu_{1β} receptors. The gray arrowhead indicates the position of the stop codon introduced to generate the deleted mutant mGlu₁-M7. *b*, HEK-293 cells transiently expressing A1R alone (lane 1), A1R plus mGlu_{1α}-FLAG (lane 2), A1R plus mGlu_{1β}-FLAG (lane 3), and A1R plus mGlu₁-M7-FLAG (lane 4) were processed for immunoprecipitation using anti-A1R antibodies (PC11-Ab; 10 μg/ml). Solubilized membranes (Crude, lanes 1–4) and immunoprecipitates (IP, lanes 5–8) were analyzed by SDS-PAGE and immunoblotted (IB) using anti-mGlu₁ antibodies (F1-Ab; 5 μg/ml). Immunoreactive bands were detected as before. IgG indicates the position of the immunoglobulins used in the immunoprecipitation.

means of ligand binding experiments performed in these cells (see “Experimental Procedures”). Cells transfected with the cDNA for A1R alone express 3.4 ± 0.4 pmol of A1R/mg protein as detected by [³H]R-PIA binding with a K_D of 27 ± 3 nM. In these cells the A1R agonist R-PIA leads to a calcium peak (Fig. 5). On the other hand, cells transfected only with the cDNA for mGlu_{1α} receptor express 3.3 ± 0.9 pmol of mGlu_{1α} receptor/mg





FIG. 5. Ca²⁺ mobilization in HEK-293 transiently expressing mGlu_{1α} and A1 receptors. Intracellular Ca²⁺ concentrations were measured in suspended cells loaded with FURA-2/AM after stimulation with the mGlu_{1α} receptor agonist quisqualic acid (100 μM) (Quis) or A1R agonist *N*⁶-(*R*)-phenylisopropyladenosine (500 nM) (R-PIA).

protein as detected by [³H]quisqualic binding with a K_D of 177 ± 46 nM, and a weak calcium peak was detected when treated with the agonist for the metabotropic glutamate receptor, quisqualic acid (Fig. 5). Interestingly, in HEK-293 cells co-transfected with both receptors (3.3 ± 0.2 pmol of A1R/mg of protein and 2.8 ± 1.5 pmol of mGlu_{1α}/mg of protein), preincubation with quisqualic acid markedly potentiated the calcium peak obtained in response to A1R activation ($140 \pm 10\%$; $n = 3$). Conversely, preincubation of co-transfected cells with the agonist for A1R led to a marked enhancement of the signal provided by quisqualic acid ($180 \pm 20\%$; $n = 3$) (Fig. 5). Quisqualic acid or R-PIA failed to bind or to provide any signal in nontransfected HEK-293 cells. These results clearly show a heterologous sensitization or synergistic effect upon mGlu_{1α} and A1 receptors activation.

Interaction of mGlu_{1α} and A1 Receptors in Primary Rat Cortical Neurons—To assess the physiological relevance of the mGlu_{1α}/A1 receptors interaction, we analyzed the distribution of both receptors in primary rat cortical neurons. Both receptors showed a similar punctate distribution throughout the proximal and distal dendrites, and the degree of co-localization at these locations was very high (Fig. 6, *a–c*). In fact, some of the mGlu_{1α} receptor- or A1R-containing puncta co-distributed with the synaptic marker protein synaptophysin (Fig. 6, *d–i*), suggesting that they could be localized to synapses. Thus, synapses are one of the specific cellular sites where mGlu_{1α} and A1 receptors interact.

Glutamate/adenosine receptors interaction may be important for modulating the role of mGlu_{1α} receptor in neurodegeneration/neuroprotection, an issue that is still controversial. When examining this role a number of factors, including the

FIG. 6. Co-localization of mGluR1 α and A1R in primary cultures of rat cortical neurons. Neurons (days in vitro 14–21) were fixed, permeabilized, and processed for immunostaining using rhodamine-conjugated anti-A1R antibody (PC21-Ab; 15 μ g/ml) and fluorescein-conjugated anti-mGlu $_{1\alpha}$ receptor antibody (F2-Ab; 15 μ g/ml) (*a–c*), anti-A1R antibody (PC21-Ab, 5 μ g/ml) and anti-synaptophysin monoclonal antibody (1/20) (*d–f*), or anti-mGlu $_{1\alpha}$ receptor antibody (F2-Ab; 5 μ g/ml) and anti-synaptophysin monoclonal antibody (1/20) (*g–i*). Primary antibodies in *d–i* were detected using fluorescein-conjugated donkey anti-mouse IgG antibody (1/50) or Texas Red-conjugated donkey anti-rabbit (1/50) (*d–i*). Cells were analyzed by double immunofluorescence with a confocal microscopy. Images show A1R receptor (*a*) in red, mGlu $_{1\alpha}$ receptor (*b*) in green, A1R (*d*) and mGlu $_{1\alpha}$ (*g*) receptors in red, and synaptophysin (*h*) in green. Superimposition of images reveals co-localization in yellow (*c, f, and i*). Scale bar, 10 μ m.



heteromeric composition of NMDA receptors, the time of exposure to drugs or to ambient glutamate, and the function of astrocytes clearing extracellular glutamate and producing neurotoxic or neuroprotective factors must be taken into account (20). On the other hand, glutamate could also modulate the well known function of adenosine as neuroprotective factor (12). It is thus likely that the interaction of mGlu $_{1\alpha}$ /A1 receptors could be beneficial in situations of enhanced neuronal activity, in which potentiation of postsynaptic adenosine A1 receptor limits evoked depolarization and results in decreased activation of voltage-dependent Ca $^{2+}$ channels and NMDA receptor ion channels, through which Ca $^{2+}$ enters cell bodies (30). We have therefore examined the effect of activating of both mGlu $_1$ and A1 adenosine receptors on NMDA-mediated neurotoxicity in primary neuronal cultures. In agreement with previously described data (20), submaximal concentrations of NMDA induced neuronal death, which was enhanced by the presence of quisqualic acid during the NMDA treatment (Fig. 7). In contrast, when the adenosine A1 receptor agonist, R-PIA, was present during the NMDA treatment, the induced neurotoxicity was reduced by nearly 50%. When added simultaneously, R-PIA reduced the enhancement of the neurotoxicity induced by quisqualic acid (Fig. 7). On the other hand, pre-exposure of neurons to R-PIA or to quisqualic acid also reduced the NMDA-induced neurotoxicity. This reduction was more marked if both quisqualic acid and R-PIA were present during the pre-exposure, showing that the simultaneous activation of both receptors appears to increase the protection of the neurons against the NMDA treatment compared with the effect evoked by either quisqualate or R-PIA applied separately. These results show the relevance of the interaction of mGlu $_{1\alpha}$ /A1 receptors and support the concept of specificity and complexity of this interaction, being the spatiotemporal segregation profile of adenosine/glutamate during synaptic activity of special importance to achieve a neuroprotective or a neurotoxic effect.




FIG. 7. Excitotoxicity in rat cortical neurons. Cortical neurons were exposed for 10 min to 30 μ M of NMDA. Quisqualic acid (*Quis*, 100 μ M) and/or R-PIA (100 nM) were transiently applied (for 1 min) 5 min prior to the addition of NMDA (*Pre-exposure*) and/or added together with NMDA for 10 min (*Treatment*). Quisqualic acid treatments were always made in the presence of 50 μ M 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX, Sigma) to block non-NMDA receptors. Death neurons were computed by assessing the propidium iodide staining in photomicrographs of 10 representative fields from each monolayer of treated neurons and expressed as percent of NMDA toxicity. Asterisks denote differences from the control (*, $p < 0.05$; **, $p < 0.01$, two-tail t test).

DISCUSSION

Here we describe a novel interaction between two unrelated G protein-coupled receptors (GPCR), namely the metabotropic glutamate type 1 α and the adenosine A1 receptors. Although the cooperativity of the agonist binding to GPCR suggested the possibility of oligomerization of G proteins and their associated receptors (31), the existence and the precise function of GPCR homo- or heteromerization has not been fully elucidated.

Metabotropic glutamate type 1 α and adenosine A1 receptors show a high degree of co-localization in co-transfected cells and in more physiological systems as neurons from rat cerebellum and from rat cortex. Both receptors co-immunoprecipitate from co-transfected cells and from rat cerebellum synaptosomes,

suggesting that mGlu_{1α} and A1 receptors interact and that this interaction is physiologically relevant. From a functional point of view, heteromerization often results in facilitatory responses or synergistic effects. Thus, GABABR1 and GABABR2 receptors need to be co-expressed and assembled into heteromers to reach the cell surface (32–35). On the other hand, two functional opioid receptors, κ and δ , can heteromerize, which changes the pharmacology of the individual receptors and potentiates signal transduction (36). Also, it has been described for heterodimerizations for the CC chemokine receptor 2 (CCR2) and the CX chemokine receptor 4 (CXCR4) and/or CC chemokine receptor 5 (CCR5) (37). Recently, it has been demonstrated that κ and δ opioid receptors can form heteromers with β_2 -adrenergic receptors affecting their trafficking properties without any significant alteration in the ligand binding or coupling properties of the receptors (38). There are also some papers reporting similar interactions between GPCR and non-GPCR proteins, for example the receptor activity-modifying protein, a small protein containing only one putative transmembrane domain and a short cytosolic tail, acting as a chaperone protein that facilitates the cell surface targeting and modulator function of the calcitonin-receptor-like receptor (39). Interestingly, recent data (40) indicated that a GPCR, the D5-dopamine receptor, physically interacts with the γ -aminobutyric acid A (GABA_A) receptor, a GABA-operated Cl⁻ channel. This physical interaction was dependent on the presence of agonist for both receptors and necessary for the functional cross-talk between the D5 and GABA_A receptors (40). In the case of cells co-expressing mGlu_{1α} and A1 receptors, a glutamate/adenosine synergism was found at the level of calcium mobilization (Fig. 5). Furthermore, in experiments of neuroprotection performed in neuronal cultures, preincubation with quisqualic acid plus adenosine was much more effective than pretreatment with any of the compounds. These results suggest that activation of mGlu_{1α} and A1 receptors in the same neuron results in synergism. Heteromerization, however, does not always lead to facilitation or synergistic events. Thus, in basal ganglia, there is an adenosine-mediated antagonism of dopaminergic neurotransmission. This antagonism is in part due to cross-talk at the level of second messengers but is also mediated by formation of adenosine/dopamine receptor heteromers (41). Although it is difficult to ascertain to what extent the antagonism is mediated by heteromerization or to interference in signaling, there is evidence indicating that both events operate and are closely interrelated. Thus, in cells where A1R and D1-dopamine receptors are present, as in nigrostriatal GABAergic neurons, adenosine leads to both the disappearance of the high affinity site of D1 receptors, probably via conformational changes in A1R/D1R heteromers, and a reduction in dopamine-induced cAMP increases, an effect due to cross-talk at the adenylate cyclase level (41).

There is experimental and molecular modeling evidence that intramembrane domains are involved in the formation of homodimers of G protein-coupled receptors. Gouldson *et al.* (42) have hypothesized that domain swapping with involvement of transmembrane regions 5 and 6 is responsible for homo- and heteromerization of G protein-coupled receptors. In contrast, heterodimerization of GABAR1 and GABABR2 receptors is mediated by the coiled-coil interaction of the C-terminal cytoplasmic tails (35). In the case of mGlu_{1α}/A1 receptors' heteromers the interaction depends on the C terminus of mGlu_{1α} receptor as its splice variant, mGlu_{1β} receptor, which has a short and different C terminus, does not interact with A1R. Also a deleted mutant of mGlu₁ receptor, close to the splice variant site and missing nearly all the C terminus of the receptor, does not interact with A1R. The co-immunoprecipita-

tion of mGlu_{1α} and A1 receptors might be due to a physical association between them, but it also could be the case that both receptors are recruited into a specific signaling complex at specific synapses via common interactions with other proteins.

One possible mechanism for this mGlu_{1α}/A1 receptor coupling is that it is directed by interactions of the cytoplasmic C terminus with specific targeting proteins. This type of targeting mechanism appears to operate for the synaptic localization of the ionotropic glutamate receptors and a number of different proteins, containing PDZ domains, which interact with specific C-terminal sequences of these receptors (43–47). Also, the EVH1-like domain (ENA/VASP homology domain 1)-containing protein, which binds specifically to the C-terminal residues of mGlu_{1α} receptor, has been described (48). This protein, termed Homer-1A, was isolated as a synaptic plasticity-regulated gene from rat hippocampus (48, 49). Additional proteins related to Homer-1A have also been described, namely Homer-1B, Homer-1C, Homer-2A, Homer 2B, Homer-2C, Homer-2D, Homer-3A, Homer-3B, Homer-3C, and Homer-3D (50–53). The ability of Homer to link mGlu_{1α} receptor to Shank, a scaffolding multimeric signaling protein, may contribute to anchoring the mGlu_{1α} receptor to specific sites at the plasma membrane (8, 9). Our efforts are directed to find a network of protein interactions that are shared by both receptors and that likely play a key role in the signaling mechanisms of both mGlu_{1α} and A1 receptors. The nature of the signaling complexes formed would depend on the type of receptors present in a given neuron, and the effect will be determined by the balance between concentrations of agonists in the synaptic cleft and timing of receptor activation. It has been proposed that the mechanism of the biphasic effects of quisqualic acid to increase NMDA toxicity if added together with NMDA or to reduce it if pretreated before NMDA is in part due to the functional switch described for the mGlu_{1α} receptor (54, 55, 20). In mixed cortical or pure hippocampal neuronal cultures a first application of 3,5-dihydroxyphenylglycine, an agonist of the group I mGlu receptors, potentiated toxicity induced by submaximal concentrations of NMDA, whereas the same drug applied shortly after a brief pre-exposure, protected against neuronal death (20). Interestingly, the switch in the regulation of excitotoxic neuronal death was sensitive to protein kinase C inhibitors (20). This mechanism may explain the opposite results obtained with group I mGlu receptors, assuming that the influence of group I mGlu receptors on excitotoxic neuronal death will depend on the “functional status” of group I mGlu receptors (naive *versus* experienced or unphosphorylated *versus* phosphorylated receptors) (20). In Fig. 7 we show that the timing in mGlu_{1α} and A1 receptors activation is very important to achieve a maximum effect in adenosine- and glutamate-mediated neuroprotection/neurodegeneration. In fact, although adenosine added together with glutamate was protective for cultured neurons, this protection was nearly total by preincubation with the metabotropic glutamate receptor agonist.

Our data provide biochemical and functional evidence for mGlu_{1α} and A1 receptor-receptor interaction. The way A1R is involved in interactions with receptors for other neurotransmitters, using different receptor system to synchronize synaptic transmission, opens new perspectives to understand the actual role of this autacoid. Since mGlu_{1α} receptors seem to be involved in the pathophysiology of neuropsychiatric diseases such as Alzheimer's and related disorders, this molecular interaction offers a new basis for the design of novel strategies to study the genesis and evolution of these diseases and of novel agents to treat them.

Acknowledgment—We acknowledge the technical help received from Susana Castel (confocal microscopy section).

REFERENCES

1. Hollmann, M., and Heinemann, S. (1994) *Annu. Rev. Neurosci.* **17**, 31–108
2. Conn, P. J., and Pin, J.-P. (1997) *Annu. Rev. Pharmacol. Toxicol.* **37**, 205–237
3. Pin, J.-P., and Duvoisin, R. (1995) *Neuropharmacology* **34**, 1–26
4. Pin, J.-P., Waeber, C., Prezeau, L., Bockaert, J., and Heinemann, S. F. (1992) *Proc. Natl. Acad. Sci. U. S. A.* **89**, 10331–10335
5. Grandes, P., Mateos, J. M., Ruegg, D., Kuhn, R., and Knopfel, T. (1994) *Neuroreport* **5**, 2249–2252
6. Ciruela, F., Robbins, M. J., Willis, A. C., and McIlhinney, R. A. J. (1999) *J. Neurochem.* **72**, 346–354
7. Ciruela, F., Soloviev, M. M., and McIlhinney, R. A. J. (1999) *FEBS Lett.* **448**, 91–94
8. Ciruela, F., Soloviev, M. M., and McIlhinney, R. A. J. (1999) *Biochem. J.* **341**, 795–803
9. Ciruela, F., Soloviev, M. M., Chan, W. Y., and McIlhinney, R. A. J. (2000) *Mol. Cell Neurosci.* **15**, 36–50
10. Phillis, J. W., and Wu, P. (1981) *Prog. Neurobiol.* **16**, 187–239
11. Palmer, T. M., and Stiles, G. L. (1995) *Neuropharmacology* **34**, 683–694
12. Dunwiddie, T. V. (1985) *Int. Rev. Neurobiol.* **27**, 63–139
13. Wu, L. G., and Saggau, P. (1994) *Neuron* **12**, 1139–1148
14. Genazzani, A. A., L'Episcopo, M. R., Casabona, G., Shinozaki, H., and Nicoletti, F. (1994) *Brain Res.* **659**, 10–16
15. Schoepp, D. D., Salhoff, C. R., Wright, R. A., Johnson, B. G., Burnett, J. P., Mayne, N. G., Belagaje, R., Wu, S., and Monn, J. A. (1996) *Neuropharmacology* **35**, 1661–1672
16. Mistry, R., Golding, N., and Challiss, R. A. (1998) *Br. J. Pharmacol.* **123**, 581–589
17. Ogata, T., Nakamura, Y., Tsuji, K., Shibata, T., Kataoka, K., and Schubert, P. (1994) *Neurosci. Lett.* **170**, 5–8
18. Toms, N. J., and Roberts, P. J. (1999) *Neuropharmacology* **38**, 1511–1517
19. Jordan, M., Schallhorn, A., and Wurm, F. M. (1996) *Nucleic Acids Res.* **24**, 596–601
20. Nicoletti, F., Bruno, V., Catania, M. V., Battaglia, G., Copani, A., Barbagnallo, G., Ceña, V., Sanchez-Prieto, J., Spano, P. F., and Pizzi, M. (1999) *Neuropharmacology* **38**, 1477–1484
21. Ciruela, F., and McIlhinney, R. A. J. (1997) *FEBS Lett.* **418**, 83–86
22. Ciruela, F., Casado, V., Mallol, J., Canela, E. I., Lluís, C., and Franco, R. (1995) *J. Neurosci. Res.* **42**, 818–828
23. Laemmli, U. K. (1970) *Nature* **227**, 680–685
24. Casado, V., Canti, C., Mallol, J., Canela, E. I., Lluís, C., and Franco, R. (1990) *J. Neurosci. Res.* **26**, 461–473
25. Casado, V., Franco, R., Mallol, J., Lluís, C., and Canela, E. I. (1992) *Biochem. J.* **281**, 477–483
26. Mirabet, M., Mallol, J., Lluís, C., and Franco, R. (1997) *Br. J. Pharmacol.* **122**, 1075–1082
27. Baude, A., Nusser, Z., Roberts, J. D. B., Mulvihill, E., McIlhinney, R. A. J., and Somogyi, P. (1993) *Neuron* **11**, 771–787
28. Ochiishi, T., Chen, L., Yukawa, A., Saitoh, Y., Sekino, Y., Arai, T., Nakata, H., and Miyamoto, H. (1999) *J. Comp. Neurol.* **411**, 301–316
29. Gao, Z., Robeva, A. S., Linden, J. (1999) *Biochem. J.* **338**, 729–736
30. Robbins, M. J., Ciruela, F., Rhodes, A., McIlhinney, R. A. J. (1999) *J. Neurochem.* **72**, 2539–2547
31. Schubert, P., Ogata, T., Marchini, C., Ferroni, S., and Rudolph, K. (1997) *Ann. N. Y. Acad. Sci.* **825**, 1–10
32. Willardson, B. M., Pou, B., Yoshida, T., and Bitensky, M. W. (1993) *J. Biol. Chem.* **268**, 6371–6382
33. Jones, K. A., Borowsky, B., Tamm, J. A., Craig, D. A., Durkin, M. M., Dai, M., Yao, W. J., Johnson, M., Gunwaldsen, C., Huang, L. Y., Tang, C., Shen, Q., Salon, J. A., Morse, K., Laz, T., Smith, K. E., Nagarathnam, D., Noble, S. A., Branchek, T. A., and Gerald, C. (1998) *Nature* **396**, 674–679
34. Kaupmann, K., Malitschek, B., Schuler, V., Heid, J., Froestl, W., Beck, P., Mosbacher, J., Bischoff, S., Kulik, A., Shigemoto, R., Karschin, A., and Bettler, B. (1998) *Nature* **396**, 683–688
35. Kuner, R., Kohr, G., Grunewald, S., Eisenhardt, G., Bach, A., and Kornau, H. C. (1999) *Science* **283**, 74–77
36. White, J. H., Wise, A., Main, M. J., Green, A., Fraser, N. J., Disney, G. H., Barnes, A. A., Emson, P., Foord, S. M., and Marshall, F. H. (1998) *Nature* **396**, 679–682
37. Jordan, B. A., and Devi, L. A. (1999) *Nature* **399**, 697–700
38. Mellado, M., Rodriguez-Frade, J. M., Vila-Coro, A. J., de Ana, A. M., and Martinez-A, C. (1999) *Nature* **400**, 723–724
39. Jordan, B. A., Trapaidze, N., Gomes, I., Nivarthi, R., and Devi, L. A. (2001) *Proc. Natl. Acad. Sci. U. S. A.* **98**, 343–348
40. McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G., and Foord, S. M. (1998) *Nature* **393**, 333–339
41. Liu, F., Wan, Q., Pristupa, Z. B., Yu, X. M., Wang, Y. T., and Niznik, H. B. (2000) *Nature* **403**, 274–280
42. Ginés, S., Hillion, J., Torvinen, M., Le Crom, S., Casadó, V., Canela, E. I., Rondin, S., Lew, J. Y., Watson, S., Zoli, M., Agnati, L. F., Vernier, P., Lluís, C., Ferré, S., Fuxe, K., and Franco, R. (2000) *Proc. Natl. Acad. Sci. U. S. A.* **97**, 8606–8611
43. Gouldson, P. R., Snell, C. R., Bywater, R. P., Higg, C., and Reynolds, C. A. (1998) *Protein Eng.* **11**, 1181–1193
44. Dong, H. L., Obrien, R. J., Fung, E. T., Lanahan, A. A., Worley, P. F., and Huganir, R. L. (1997) *Nature* **386**, 279–284
45. Hunt, C. A., Schenker, L. J., and Kennedy, M. B. (1996) *J. Neurosci.* **16**, 1380–1388
46. Kim, E., Cho, K. O., Rothschild, A., and Sheng, M. (1996) *Neuron* **17**, 103–113
47. Muller, B. M., Kistner, U., Kindler, S., Chung, W. J., Kuhlendahl, S., Fenster, S. D., Lau, L. F., Veh, R. W., Huganir, R. L., Gundelfinger, E. D., and Garner, C. C. (1996) *Neuron* **17**, 255–265
48. Niethammer, M., Kim, E., and Sheng, M. (1996) *J. Neurosci.* **16**, 2157–2163
49. Brakeman, P. R., Lanahan, A. A., O'Brien, R., Roche, K., Barnes, C. A., Huganir, R. L., and Worley, P. F. (1997) *Nature* **386**, 284–288
50. Kato, A., Ozawa, F., Saitoh, Y., Hirai, K., and Inokuchi, K. (1997) *FEBS Lett.* **412**, 183–189
51. Kato, A., Ozawa, F., Saitoh, Y., Fukazawa, Y., Sugiyama, H., and Inokuchi, K. (1998) *J. Biol. Chem.* **273**, 23969–23975
52. Soloviev, M. M., Ciruela, F., Chan, W.-Y., and McIlhinney, R. A. J. (2000) *J. Mol. Biol.* **295**, 1185–1200
53. Xiao, B., Tu, J. C., Petralia, R. S., Yuan, J. P., Doan, A., Breder, C. D., Ruggiero, A., Lanahan, A. A., Wenthold, R. J., and Worley, P. F. (1998) *Neuron* **21**, 707–716
54. Beneken, J., Tu, J. C., Xiao, B., Nuriya, M., Yuan, J. P., Worley, P. F., and Leahy, D. J. (2000) *Neuron* **26**, 143–154
55. Herrero, I., Miras-Portugal, M. T., and Sanchez-Prieto, J. (1998) *J. Biol. Chem.* **273**, 1951–1958
56. Rodriguez-Moreno, A., Sistiaga, A., Lerma, J., and Sanchez-Prieto, J. (1998) *Neuron* **21**, 1477–1486

Metabotropic Glutamate 1 α and Adenosine A1 Receptors Assemble into Functionally Interacting Complexes

Francisco Ciruela, Marisol Escriche, Javier Burgueño, Ester Angulo, Vicent Casadó, Mikhail M. Soloviev, Enric I. Canela, Josefa Mallol, Wai-Yee Chan, Carmen Lluís, R. A. Jeffrey McIlhinney and Rafael Franco

J. Biol. Chem. 2001, 276:18345-18351.

doi: 10.1074/jbc.M006960200 originally published online February 13, 2001

Access the most updated version of this article at doi: [10.1074/jbc.M006960200](https://doi.org/10.1074/jbc.M006960200)

Alerts:

- [When this article is cited](#)
- [When a correction for this article is posted](#)

[Click here](#) to choose from all of JBC's e-mail alerts

This article cites 56 references, 12 of which can be accessed free at <http://www.jbc.org/content/276/21/18345.full.html#ref-list-1>